Neuropsychiatric Function Improvement in Pediatric Patients With Phenylketonuria.

[1]  S. Waisbren,et al.  Improved attention linked to sustained phenylalanine reduction in adults with early‐treated phenylketonuria , 2021, American journal of medical genetics. Part A.

[2]  S. Christ,et al.  Inter- and intra-tract analysis of white matter abnormalities in individuals with early-treated phenylketonuria (PKU). , 2020, Molecular genetics and metabolism.

[3]  F. Spronsen,et al.  Tetrahydrobiopterin treatment in phenylketonuria: A repurposing approach , 2020, Journal of inherited metabolic disease.

[4]  M. Walterfang,et al.  Psychiatric and Cognitive Aspects of Phenylketonuria: The Limitations of Diet and Promise of New Treatments , 2019, Front. Psychiatry.

[5]  I. Schwartz,et al.  Attention-deficit hyperactivity disorder in Brazilian patients with phenylketonuria , 2018, Acta Neurologica Belgica.

[6]  C. Hollak,et al.  Long-Term Follow-Up of Cognition and Mental Health in Adult Phenylketonuria: A PKU-COBESO Study , 2017, Behavior Genetics.

[7]  T. van Amelsvoort,et al.  Cerebral dopamine deficiency, plasma monoamine alterations and neurocognitive deficits in adults with phenylketonuria , 2017, Psychological Medicine.

[8]  D. Bilder,et al.  Neuropsychiatric comorbidities in adults with phenylketonuria: A retrospective cohort study. , 2017, Molecular genetics and metabolism.

[9]  S. Cederbaum,et al.  Adherence to clinic recommendations among patients with phenylketonuria in the United States. , 2017, Molecular genetics and metabolism.

[10]  U. Lichter-Konecki,et al.  Phenylketonuria (PKU): A problem solved? , 2015, Molecular genetics and metabolism reports.

[11]  S. Stahl,et al.  A randomized, placebo-controlled, double-blind study of sapropterin to treat ADHD symptoms and executive function impairment in children and adults with sapropterin-responsive phenylketonuria. , 2015, Molecular genetics and metabolism.

[12]  D. Elbourne,et al.  Systematic review of the Hawthorne effect: New concepts are needed to study research participation effects☆ , 2014, Journal of clinical epidemiology.

[13]  John J. Mitchell,et al.  Phenylalanine hydroxylase deficiency: diagnosis and management guideline , 2013, Genetics in Medicine.

[14]  Amanda J. Moffitt,et al.  The effects of tetrahydrobiopterin (BH4) treatment on brain function in individuals with phenylketonuria☆ , 2013, NeuroImage: Clinical.

[15]  P. Fernhoff,et al.  Safety of extended treatment with sapropterin dihydrochloride in patients with phenylketonuria: results of a phase 3b study. , 2011, Molecular genetics and metabolism.

[16]  John J. Mitchell,et al.  Phenylalanine hydroxylase deficiency , 2011, Genetics in Medicine.

[17]  Larissa V Furtado,et al.  Correlation of age-specific phenylalanine levels with intellectual outcome in patients with phenylketonuria , 2011, Journal of Inherited Metabolic Disease.

[18]  B. Burton,et al.  Tetrahydrobiopterin therapy for phenylketonuria in infants and young children. , 2011, The Journal of pediatrics.

[19]  R. Carpenter,et al.  Dietary treatment of phenylketonuria: the effect of phenylalanine on reaction time , 2011, Journal of Inherited Metabolic Disease.

[20]  G. Enns,et al.  Suboptimal outcomes in patients with PKU treated early with diet alone: revisiting the evidence. , 2010, Molecular genetics and metabolism.

[21]  J. Vockley,et al.  Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study. , 2009, The Journal of pediatrics.

[22]  S. Cederbaum,et al.  The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6R-tetrahydrobiopterin): a phase II, multicentre, open-label, screening study , 2007, Journal of Inherited Metabolic Disease.

[23]  S. Wood,et al.  Are Neuropsychological Impairments in Children with Early-Treated Phenylketonuria (PKU) Related to White Matter Abnormalities or Elevated Phenylalanine Levels? , 2007, Developmental neuropsychology.

[24]  S. Waisbren,et al.  Phenylalanine blood levels and clinical outcomes in phenylketonuria: a systematic literature review and meta-analysis. , 2007, Molecular genetics and metabolism.

[25]  A. Chakrapani,et al.  Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study , 2007, The Lancet.

[26]  S. Packman,et al.  Executive functioning in children and adolescents with phenylketonuria , 2007, Clinical genetics.

[27]  A. Fox,et al.  Meta-Analysis of Neuropsychological Symptoms of Adolescents and Adults with PKU , 2007, Neuropsychology Review.

[28]  R. Artuch,et al.  School performance in early and continuously treated phenylketonuria. , 2005, Pediatric neurology.

[29]  R. Artuch,et al.  Cognitive functions in classic phenylketonuria and mild hyperphenylalaninaemia: experience in a paediatric population. , 2005, Developmental medicine and child neurology.

[30]  C. Vladutiu,et al.  Prevalence of stimulant use for attentional dysfunction in children with phenylketonuria , 2004, Journal of Inherited Metabolic Disease.

[31]  G. Levi,et al.  Executive function impairment in early-treated PKU subjects with normal mental development , 2004, Journal of Inherited Metabolic Disease.

[32]  S. Waisbren,et al.  Timing is everything: executive functions in children exposed to elevated levels of phenylalanine. , 2003, Neuropsychology.

[33]  J. Sergeant,et al.  Sustained attention and inhibition of cognitive interference in treated phenylketonuria: associations with concurrent and lifetime phenylalanine concentrations , 2002, Neuropsychologia.

[34]  J. Sergeant,et al.  Inhibition of Prepotent Responding and Attentional Flexibility in Treated Phenylketonuria , 2002, Developmental neuropsychology.

[35]  A. Boneh,et al.  How practical are recommendations for dietary control in phenylketonuria? , 2002, The Lancet.

[36]  Robert Reid,et al.  Parent Ratings of Attention-Deficit/Hyperactivity Disorder Symptoms: Factor Structure and Normative Data , 1998 .

[37]  J. Jenkins,et al.  Magnetic resonance imaging in phenylketonuria: reversal of cerebral white matter change. , 1995, The Journal of pediatrics.

[38]  A. Rupp,et al.  Sustained attention in adult phenylketonuria: the influence of the concurrent phenylalanine-blood-level. , 1994, Journal of clinical and experimental neuropsychology.

[39]  D. Clark,et al.  Reliability and validity of the Hamilton Anxiety Rating Scale in an adolescent sample. , 1994, Journal of the American Academy of Child and Adolescent Psychiatry.

[40]  M. Hamilton,et al.  Development of a rating scale for primary depressive illness. , 1967, The British journal of social and clinical psychology.

[41]  M. Hamilton.  A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.

[42]  M. Hamilton.  The assessment of anxiety states by rating. , 1959, The British journal of medical psychology.

[43]  Mayara Thays Beckhauser,et al.  Attention Deficit Disorder with Hyperactivity Symptoms in Early-Treated Phenylketonuria Patients , 2020, Iranian journal of child neurology.

[44]  K. Wyrwich,et al.  Content Validity of the ADHD Rating Scale (ADHD RS-IV) and Adult ADHD Self-Report Scale (ASRS) in Phenylketonuria: , 2016 .

[45]  H. Coon,et al.  A diversified approach for PKU treatment: routine screening yields high incidence of psychiatric distress in phenylketonuria clinics. , 2013, Molecular genetics and metabolism.

[46]  P. Anderson,et al.  White matter pathology in phenylketonuria. , 2010, Molecular genetics and metabolism.

[47]  S. Christ,et al.  Executive function in early-treated phenylketonuria: profile and underlying mechanisms. , 2010, Molecular genetics and metabolism.

[48]  I. Heuser,et al.  The Hamilton Anxiety Scale: reliability, validity and sensitivity to change in anxiety and depressive disorders. , 1988, Journal of affective disorders.

[49]  D. Freides,et al.  Biochemical and neuropsychological effects of elevated plasma phenylalanine in patients with treated phenylketonuria. A model for the study of phenylalanine and brain function in man. , 1985, The Journal of clinical investigation.